Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.06
ENDP's Cash-to-Debt is ranked lower than
94% of the 719 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. ENDP: 0.06 )
Ranked among companies with meaningful Cash-to-Debt only.
ENDP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 1.05 Max: No Debt
Current: 0.06
Equity-to-Asset 0.19
ENDP's Equity-to-Asset is ranked lower than
92% of the 660 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.62 vs. ENDP: 0.19 )
Ranked among companies with meaningful Equity-to-Asset only.
ENDP' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.08  Med: 0.45 Max: 0.76
Current: 0.19
0.08
0.76
Piotroski F-Score: 3
Altman Z-Score: -0.97
Beneish M-Score: -3.78
WACC vs ROIC
2.11%
-23.97%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -86.57
ENDP's Operating Margin % is ranked lower than
87% of the 672 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.86 vs. ENDP: -86.57 )
Ranked among companies with meaningful Operating Margin % only.
ENDP' s Operating Margin % Range Over the Past 10 Years
Min: -86.57  Med: 21.38 Max: 30.74
Current: -86.57
-86.57
30.74
Net Margin % -83.46
ENDP's Net Margin % is ranked lower than
87% of the 673 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. ENDP: -83.46 )
Ranked among companies with meaningful Net Margin % only.
ENDP' s Net Margin % Range Over the Past 10 Years
Min: -83.46  Med: -9.43 Max: 20.95
Current: -83.46
-83.46
20.95
ROE % -62.20
ENDP's ROE % is ranked lower than
89% of the 690 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.66 vs. ENDP: -62.20 )
Ranked among companies with meaningful ROE % only.
ENDP' s ROE % Range Over the Past 10 Years
Min: -85.73  Med: -12.88 Max: 20.43
Current: -62.2
-85.73
20.43
ROA % -19.04
ENDP's ROA % is ranked lower than
81% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.48 vs. ENDP: -19.04 )
Ranked among companies with meaningful ROA % only.
ENDP' s ROA % Range Over the Past 10 Years
Min: -19.91  Med: -2.47 Max: 14.68
Current: -19.04
-19.91
14.68
ROC (Joel Greenblatt) % -510.10
ENDP's ROC (Joel Greenblatt) % is ranked lower than
88% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.44 vs. ENDP: -510.10 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ENDP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -510.1  Med: 81.95 Max: 718.27
Current: -510.1
-510.1
718.27
3-Year Revenue Growth Rate 0.50
ENDP's 3-Year Revenue Growth Rate is ranked lower than
68% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. ENDP: 0.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ENDP' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -12  Med: 19.6 Max: 26.9
Current: 0.5
-12
26.9
GuruFocus has detected 6 Warning Signs with Endo International PLC $ENDP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ENDP's 10-Y Financials

Financials (Next Earnings Date: 2017-05-28 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ENDP Guru Trades in Q1 2016

Jim Simons 569,260 sh (New)
David Dreman 792 sh (New)
Paul Tudor Jones 64,148 sh (+700.95%)
John Paulson 9,517,500 sh (+188.22%)
RS Investment Management 1,368,053 sh (+151.67%)
Wallace Weitz 968,093 sh (+41.34%)
George Soros 103,200 sh (unchged)
John Paulson 119,900 sh (unchged)
Louis Moore Bacon Sold Out
John Griffin Sold Out
George Soros Sold Out
Mario Gabelli Sold Out
Andreas Halvorsen 4,468,744 sh (-1.15%)
Diamond Hill Capital 12,443 sh (-8.28%)
Pioneer Investments 140,434 sh (-38.71%)
Steven Cohen 228,000 sh (-42.50%)
» More
Q2 2016

ENDP Guru Trades in Q2 2016

Arnold Schneider 445,225 sh (New)
Joel Greenblatt 1,036,004 sh (New)
David Dreman 10,670 sh (+1247.22%)
Steven Cohen 2,521,434 sh (+1005.89%)
RS Investment Management 1,374,185 sh (+0.45%)
John Paulson 119,900 sh (unchged)
Andreas Halvorsen Sold Out
Diamond Hill Capital Sold Out
Wallace Weitz Sold Out
John Paulson 8,956,300 sh (-5.90%)
Paul Tudor Jones 17,296 sh (-73.04%)
Pioneer Investments 28,618 sh (-79.62%)
Jim Simons 11,005 sh (-98.07%)
» More
Q3 2016

ENDP Guru Trades in Q3 2016

Mario Gabelli 46,700 sh (New)
Larry Robbins 4,250,784 sh (New)
Ray Dalio 887,293 sh (New)
Jim Simons 206,060 sh (+1772.42%)
Paul Tudor Jones 59,815 sh (+245.83%)
Arnold Schneider 479,006 sh (+7.59%)
Pioneer Investments 28,618 sh (unchged)
David Dreman 10,670 sh (unchged)
John Paulson 7,953,900 sh (-11.19%)
Steven Cohen 1,762,300 sh (-30.11%)
Joel Greenblatt 28,677 sh (-97.23%)
» More
Q4 2016

ENDP Guru Trades in Q4 2016

Jim Simons 1,525,860 sh (+640.49%)
Ray Dalio 1,537,036 sh (+73.23%)
Arnold Schneider 559,211 sh (+16.74%)
Mario Gabelli 47,500 sh (+1.71%)
Pioneer Investments 28,618 sh (unchged)
Larry Robbins 4,250,784 sh (unchged)
Steven Cohen Sold Out
David Dreman Sold Out
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
John Paulson 7,839,900 sh (-1.43%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ENDP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:HZNP, NAS:IRWD, NAS:AKRX, NAS:PCRX, OTCPK:IZQVF, NAS:RDUS, NAS:SUPN, NAS:MDCO, OTCPK:KSPHF, NAS:EGRX, NYSE:CTLT, OTCPK:EVTCY, OTCPK:KHTRF, OTCPK:GNMLF, NAS:SGYP, OTCPK:STDAF, NYSE:DPLO, OTCPK:TWMJF, NAS:MNTA, NAS:DEPO » details
Traded in other countries:ENDP.Canada, EO7.Germany,
Endo International PLC is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products as well as medical devices.

After a string of acquisitions and divestitures, Endo is a specialty pharmaceutical company with a considerable presence in pain management. Recent acquisitions of Auxilium and Par, however, have increased the company's presence in urology and generics, respectively. Branded drugs represent approximately 30% of revenue with the remainder in generics.

Guru Investment Theses on Endo International PLC

Weitz Funds Comments on Endo International - Jan 26, 2017

Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Endo experienced significantly worse-than-anticipated erosion at Qualitest, its legacy generic drug platform. The competitive environment changed quickly, and we were slow to recognize it. After conversations with both management and a couple of the larger drug buying consortiums, we could not gain comfort in the durability of Endo’s now lower earnings base. The company’s balance sheet and potential legal obligations (liabilities relating to the company’s legacy vaginal mesh products) leave less room for error given growth challenges on the branded side of Endo’s business. Considering the erosion in our investment thesis, questions about management’s ability to identify and navigate risk, and a growing list of unknowns surrounding the business, we elected to close our position in the second calendar quarter and refocus our capital in more attractive opportunities.



From Weitz Investment Management's Value Fund fourth quarter 2016 commentary.



Check out Wallace Weitz latest stock trades

Wally Weitz Comments on Endo - Nov 08, 2016

Endo (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Endo experienced significantly worse-than-anticipated erosion at Qualitest, its legacy generic drug platform. Simply put, our analysis of the company’s competitive positioning in controlled substance generics was wrong. The competitive environment changed quickly, and we were slow to recognize it. After conversations with both management and a couple of the larger drug buying consortiums, we could not gain comfort in the durability of Endo’s now lower earnings base. The company’s balance sheet and potential legal obligations (liabilities relating to the company’s legacy vaginal mesh products) leave less room for error given growth challenges on the branded side of Endo’s business. Considering the erosion in our investment thesis, questions about management’s ability to identify and navigate risk, and a growing list of unknowns surrounding the business, we elected to close our position in the second calendar quarter and refocus our capital in more attractive opportunities.

From Wallace Weitz (Trades, Portfolio)'s Partners Value Fund third-quarter commentary.

Check out Wallace Weitz latest stock trades

Weitz Funds Comments on Endo International - Jul 20, 2016

Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Endo experienced significantly worse than anticipated erosion at Qualitest, its legacy generic drug platform. Simply put, our analysis of the company’s competitive positioning in controlled substance generics was wrong. The competitive environment changed quickly and we were slow to recognize it. After conversations with management and a couple of the larger drug buying consortiums, we could not gain comfort in the durability of Endo’s now lower earnings base. The company’s balance sheet and potential legal obligations (liabilities relating to the company’s legacy vaginal mesh products) leave less room for error given growth challenges on the branded side of Endo’s business. Given the erosion in our investment thesis, questions about management’s ability to identify and navigate risk, and a growing list of unknowns surrounding the business, we elected to close our position and refocus our capital in more attractive opportunities.



From Weitz Value Fund's Value second quarter 2016 commentary.



Check out Wallace Weitz latest stock trades

Wallace Weitz Comments on Endo International - Apr 22, 2016

Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded and generic pharmaceutical products and medical devices. Several developments contributed to a difficult 12-month period for Endo’s stock. Growth in the company’s branded drug division has been disappointing, owing in part to poor results from several drugs Endo inherited from its acquisition of Auxilium Pharmaceuticals roughly ayear ago. In addition, pricing pressure in the company’s legacy Qualitest generics business increased, muting the segment’s near-term (and potentially long-term) growth trajectory. Finally, liabilities relating to the company’s legacy vaginal mesh products increased, following an influx of claims late in 2015. While our business value estimate for Endo has come down, the stock price has declined far more significantly. Using conservative assumptions for the company’s business over the next several years, we believe Endo has significant upside potential if management can execute on its growth plans for XIAFLEX (attractive injectible franchise) and BELBUCA (pain patch).

From Wallace Weitz (Trades, Portfolio)'s Weitz Value Fund 1st quarter 2016 commentary.

Check out Wallace Weitz latest stock trades

Wallace Weitz Comments on Endo International - Jan 22, 2016

Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Amid widespread pressure in the pharmaceutical market, news at Endo was mixed during the quarter. The company recorded a significant impairment charge in November relating to its recent acquisition of Auxilium. While management had hinted at some early challenges with Auxilium’s topical testosterone products and STENDRA (a competitor to Viagra in the ED market), CEO Rajiv De Silva formally announced Endo would be de-emphasizing and/or selling these products. This decision increases Endo’s dependence upon its primary growth drivers (recently acquired Par Pharmaceutical, Xiaflex and new pain product BELBUCA), which we believe will drive attractive organic sales growth during the next several years. News of a renewed 8-year commercial agreement with Novartis for Voltaren Gel was a distinct positive. We added to our position below $60 per share during the quarter.

From Wallace Weitz (Trades, Portfolio)'s fourth quarter 2015 Value Fund commentary.

Check out Wallace Weitz latest stock trades

Top Ranked Articles about Endo International PLC

Weitz Funds Comments on Endo International Guru stock highlight
Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Endo experienced significantly worse-than-anticipated erosion at Qualitest, its legacy generic drug platform. The competitive environment changed quickly, and we were slow to recognize it. After conversations with both management and a couple of the larger drug buying consortiums, we could not gain comfort in the durability of Endo’s now lower earnings base. The company’s balance sheet and potential legal obligations (liabilities relating to the company’s legacy vaginal mesh products) leave less room for error given growth challenges on the branded side of Endo’s business. Considering the erosion in our investment thesis, questions about management’s ability to identify and navigate risk, and a growing list of unknowns surrounding the business, we elected to close our position in the second calendar quarter and refocus our capital in more attractive opportunities. Read more...
Wally Weitz Comments on Endo Guru stock highlight
Endo (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Endo experienced significantly worse-than-anticipated erosion at Qualitest, its legacy generic drug platform. Simply put, our analysis of the company’s competitive positioning in controlled substance generics was wrong. The competitive environment changed quickly, and we were slow to recognize it. After conversations with both management and a couple of the larger drug buying consortiums, we could not gain comfort in the durability of Endo’s now lower earnings base. The company’s balance sheet and potential legal obligations (liabilities relating to the company’s legacy vaginal mesh products) leave less room for error given growth challenges on the branded side of Endo’s business. Considering the erosion in our investment thesis, questions about management’s ability to identify and navigate risk, and a growing list of unknowns surrounding the business, we elected to close our position in the second calendar quarter and refocus our capital Read more...
Healthcare Growth Stocks in the S&P 500: Part 2 Weakness in the healthcare sector has created buying opportunities in 7 companies
Introduction Read more...
Healthcare Growth Stocks in the S&P 500: Part 2 Weakness in the healthcare sector has created buying opportunities with 7 companies
Introduction Read more...
Weitz Funds Comments on Endo International Guru stock highlight
Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Endo experienced significantly worse than anticipated erosion at Qualitest, its legacy generic drug platform. Simply put, our analysis of the company’s competitive positioning in controlled substance generics was wrong. The competitive environment changed quickly and we were slow to recognize it. After conversations with management and a couple of the larger drug buying consortiums, we could not gain comfort in the durability of Endo’s now lower earnings base. The company’s balance sheet and potential legal obligations (liabilities relating to the company’s legacy vaginal mesh products) leave less room for error given growth challenges on the branded side of Endo’s business. Given the erosion in our investment thesis, questions about management’s ability to identify and navigate risk, and a growing list of unknowns surrounding the business, we elected to close our position and refocus our capital in more attractive opportunities.
From Read more...
Wally Weitz Drops Falling Drug Stock Endo but Sees 'Upside Potential' Possibly short-term headwinds prompted 75 percent market sell-off this year
Wally Weitz, founder and chief investment officer of Weitz Investment Management, informed clients via a one-off note Thursday that his firm exited it entire position in pharmaceutical company Endo International, whose stock has dwindled to a quarter of its market value year to date. Read more...
Wallace Weitz Comments on Endo International Guru stock highlight
Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded and generic pharmaceutical products and medical devices. Several developments contributed to a difficult 12-month period for Endo’s stock. Growth in the company’s branded drug division has been disappointing, owing in part to poor results from several drugs Endo inherited from its acquisition of Auxilium Pharmaceuticals roughly ayear ago. In addition, pricing pressure in the company’s legacy Qualitest generics business increased, muting the segment’s near-term (and potentially long-term) growth trajectory. Finally, liabilities relating to the company’s legacy vaginal mesh products increased, following an influx of claims late in 2015. While our business value estimate for Endo has come down, the stock price has declined far more significantly. Using conservative assumptions for the company’s business over the next several years, we believe Endo has significant upside potential if management can execute on its growth plans for XIAFLEX (attractive injectible franchise) and BELBUCA (pain Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 2.75
ENDP's Forward PE Ratio is ranked higher than
98% of the 89 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.46 vs. ENDP: 2.75 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 0.83
ENDP's PB Ratio is ranked higher than
92% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.93 vs. ENDP: 0.83 )
Ranked among companies with meaningful PB Ratio only.
ENDP' s PB Ratio Range Over the Past 10 Years
Min: 0.53  Med: 2.53 Max: 17.5
Current: 0.83
0.53
17.5
PS Ratio 0.55
ENDP's PS Ratio is ranked higher than
90% of the 727 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.85 vs. ENDP: 0.55 )
Ranked among companies with meaningful PS Ratio only.
ENDP' s PS Ratio Range Over the Past 10 Years
Min: 0.55  Med: 2.3 Max: 6
Current: 0.55
0.55
6
Price-to-Free-Cash-Flow 6.09
ENDP's Price-to-Free-Cash-Flow is ranked higher than
92% of the 228 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.42 vs. ENDP: 6.09 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ENDP' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 4.69  Med: 9.48 Max: 250.64
Current: 6.09
4.69
250.64
Price-to-Operating-Cash-Flow 4.22
ENDP's Price-to-Operating-Cash-Flow is ranked higher than
92% of the 290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.18 vs. ENDP: 4.22 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ENDP' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.02  Med: 9.09 Max: 212.54
Current: 4.22
4.02
212.54
EV-to-EBIT -2.87
ENDP's EV-to-EBIT is ranked lower than
99.99% of the 545 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.11 vs. ENDP: -2.87 )
Ranked among companies with meaningful EV-to-EBIT only.
ENDP' s EV-to-EBIT Range Over the Past 10 Years
Min: -33.3  Med: 8.15 Max: 77.3
Current: -2.87
-33.3
77.3
EV-to-EBITDA -4.03
ENDP's EV-to-EBITDA is ranked lower than
99.99% of the 573 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.30 vs. ENDP: -4.03 )
Ranked among companies with meaningful EV-to-EBITDA only.
ENDP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -139  Med: 8.3 Max: 29.3
Current: -4.03
-139
29.3
Current Ratio 0.98
ENDP's Current Ratio is ranked lower than
88% of the 614 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. ENDP: 0.98 )
Ranked among companies with meaningful Current Ratio only.
ENDP' s Current Ratio Range Over the Past 10 Years
Min: 0.98  Med: 1.73 Max: 3.06
Current: 0.98
0.98
3.06
Quick Ratio 0.77
ENDP's Quick Ratio is ranked lower than
84% of the 613 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.73 vs. ENDP: 0.77 )
Ranked among companies with meaningful Quick Ratio only.
ENDP' s Quick Ratio Range Over the Past 10 Years
Min: 0.77  Med: 1.47 Max: 2.88
Current: 0.77
0.77
2.88
Days Inventory 89.46
ENDP's Days Inventory is ranked higher than
64% of the 626 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 115.23 vs. ENDP: 89.46 )
Ranked among companies with meaningful Days Inventory only.
ENDP' s Days Inventory Range Over the Past 10 Years
Min: 80.55  Med: 99.98 Max: 148.08
Current: 89.46
80.55
148.08
Days Sales Outstanding 90.30
ENDP's Days Sales Outstanding is ranked lower than
60% of the 571 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.23 vs. ENDP: 90.30 )
Ranked among companies with meaningful Days Sales Outstanding only.
ENDP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 71.33  Med: 98.15 Max: 171.52
Current: 90.3
71.33
171.52
Days Payable 17.55
ENDP's Days Payable is ranked lower than
93% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.13 vs. ENDP: 17.55 )
Ranked among companies with meaningful Days Payable only.
ENDP' s Days Payable Range Over the Past 10 Years
Min: 17.55  Med: 120.4 Max: 300.35
Current: 17.55
17.55
300.35

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -24.60
ENDP's 3-Year Average Share Buyback Ratio is ranked lower than
84% of the 441 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.00 vs. ENDP: -24.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ENDP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -26.1  Med: -4.75 Max: 4.7
Current: -24.6
-26.1
4.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.42
ENDP's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
96% of the 314 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.37 vs. ENDP: 0.42 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ENDP' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.41  Med: 0.76 Max: 2.04
Current: 0.42
0.41
2.04
Price-to-Median-PS-Value 0.24
ENDP's Price-to-Median-PS-Value is ranked higher than
97% of the 664 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.20 vs. ENDP: 0.24 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ENDP' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.24  Med: 1.44 Max: 2.14
Current: 0.24
0.24
2.14
Price-to-Peter-Lynch-Fair-Value 4.69
ENDP's Price-to-Peter-Lynch-Fair-Value is ranked lower than
99.99% of the 173 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.61 vs. ENDP: 4.69 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ENDP' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0  Med: 0.8 Max: 4.85
Current: 4.69
0
4.85
Earnings Yield (Greenblatt) % -34.76
ENDP's Earnings Yield (Greenblatt) % is ranked lower than
91% of the 788 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. ENDP: -34.76 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ENDP' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -34.84  Med: 8.3 Max: 26.8
Current: -34.76
-34.84
26.8
Forward Rate of Return (Yacktman) % 47.83
ENDP's Forward Rate of Return (Yacktman) % is ranked higher than
92% of the 364 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.76 vs. ENDP: 47.83 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ENDP' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 4.3  Med: 30.6 Max: 63.3
Current: 47.83
4.3
63.3

More Statistics

Revenue (TTM) (Mil) $4,010
EPS (TTM) $ -15.03
Beta-0.18
Short Percentage of Float9.99%
52-Week Range $9.70 - 35.34
Shares Outstanding (Mil)222.96

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 3,523 3,304 3,357
EPS ($) 3.59 3.34 3.62
EPS without NRI ($) 3.59 3.34 3.62
EPS Growth Rate
(Future 3Y To 5Y Estimate)
-2.89%
Dividends per Share ($)
» More Articles for NAS:ENDP

Headlines

Articles On GuruFocus.com
Aytu BioScience May Lead the Way in Low T Feb 28 2017 
Weitz Funds Comments on Endo International Jan 26 2017 
4 Stocks Reach Their 3-Year Lows Jan 21 2017 
Wally Weitz Comments on Endo Nov 08 2016 
Wally Weitz's Partners Value Fund 3rd Quarter Commentary Nov 08 2016 
Healthcare Growth Stocks in the S&P 500: Part 2 Aug 12 2016 
Healthcare Growth Stocks in the S&P 500: Part 2 Aug 12 2016 
US Market Indexes Reach New Highs Aug 09 2016 
Weitz Funds Comments on Endo International Jul 20 2016 
Wally Weitz's Partners Value Fund 2Q 2016 Quarterly Commentary Jul 20 2016 

More From Other Websites
BioDelivery (BDSI) Q4 Loss Wider Than Expected; Sales Meet Mar 20 2017
Endo's (ENDP) Opana ER's Risk Benefit Evaluated by FDA Mar 16 2017
Frontier Communications, Rubicon Project Plunge into Wednesday’s 52-Week Low Club Mar 15 2017
FDA panel: Endo opioid painkiller's risks outweigh its benefits Mar 15 2017
How Endo's FDA Committee Vote Affects Egalet Mar 15 2017
[$$] FDA Advisory Panel Says Benefits of Painkiller Opana ER No Longer Outweigh Risks Mar 14 2017
Endo Statement On FDA Advisory Committees' Vote Related To OPANA® ER Mar 14 2017
Endo Statement On FDA Advisory Committees' Vote Related To OPANA® ER Mar 14 2017
FDA deals blow to Endo over Opana ER Pain Med Mar 14 2017
Risks of Endo's opioid painkiller outweigh benefits: FDA panel Mar 14 2017
[$$] FDA Panel: Painkiller Opana ER Benefits No Longer Outweigh Risks Mar 14 2017
FDA: Risk of Endo's opioid painkiller outweigh benefits Mar 14 2017
Risk of Endo's opioid painkiller outweigh benefits: FDA Panel Mar 14 2017
New Strong Sell Stocks for March 9th Mar 09 2017
Why Endo International (ENDP) Could Be Positioned for a Slump Mar 08 2017
Trump’s Tweets Trigger a Sell-Off in the Healthcare Sector Mar 08 2017
ENDO INTERNATIONAL PLC Financials Mar 07 2017
ETFs with exposure to Endo International Plc : March 6, 2017 Mar 06 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)